#Cambridge #United Kingdom #bit.bio #GFP ioMicroglia #ioTracker Cells

bit.bio Launches ioTracker Cells Range at SLAS 2025

On January 27, 2025, bit.bio, a leader in cell programming technology, proudly unveiled its new line of ioTracker Cells at the Society for Laboratory Automation and Screening (SLAS) conference held in San Diego, California. These innovative cells offer enhanced visualization capabilities crucial for recent developments in neuroscience, specifically focusing on neurodegenerative disease research. The initial product showcased under this range is GFP ioMicroglia, engineered to facilitate the tracking and isolation of cells that play vital roles in neuroinflammatory responses.

A Breakthrough for Researchers

For the first time, researchers can effectively track and isolate consistent, scalable, and defined human induced pluripotent stem cell (iPSC)-derived cells. This capability opens doors to a plethora of applications, particularly in drug discovery aimed at addressing complex neurodegenerative diseases such as Alzheimer’s and Parkinson’s.

Microglia are known as the brain's primary immune cells, responding to various signals from injury or disease. The GFP ioMicroglia cells are derived from bit.bio's acclaimed wild-type ioMicroglia and maintain the same functional characteristics. They are specifically tailored to facilitate deeper insights into intercellular interactions, thereby advancing purity in research outcomes.

According to Jonathan Milner, CEO of bit.bio, the launch of ioTracker Cells reinforces the company’s commitment to providing powerful tools for biomedical research and drug discovery. He emphasized, "This new range supports our mission by enabling researchers to explore the complexities of the human brain and enhance our understanding of neurodegenerative diseases."

Innovative Features of ioTracker Cells

The ioTracker Cells are manufactured utilizing bit.bio's proprietary opti-ox™ technology, which guarantees remarkable consistency, functionality, and scalability. This extensive portfolio now encompasses 46 unique products designed to cater to diverse research needs, including ioWild Type Cells and ioDisease Model Cells, alongside the newly introduced ioTracker Cells.

The GFP ioMicroglia can express green fluorescent protein, providing significant advantages for live-cell imaging assays. The cells are assay-ready within just ten days and are ideally suited for co-culturing with other neural cell types, enhancing the experimental capabilities of researchers focused on neurobiology. Furthermore, they simplify assessments of microglial motility and morphology, contributing to more efficient fluorescent activated cell sorting (FACS) workflows.

Farah Patell-Socha, Vice President of Products at bit.bio, also noted the significance of these cells in facilitating a more refined study of neuroinflammation and neurogenesis. The new ioTracker Cells serve as an effective tool to better understand the complexities of intercellular dynamics in disease settings. Their integration with CRISPR-Ready cells provides scientists with a comprehensive toolkit to further neurodegenerative disease research.

Transforming Drug Discovery Workflows

bit.bio is dedicated to fostering innovation within the scientific community by manufacturing human cells that accelerate drug discovery processes. The cells derived from iPSCs are poised to transform approaches to understanding and treating diseases. With global shipping options available, bit.bio makes these advanced tools accessible to scientists worldwide.

The ioTracker Cells represent a strategic enhancement to bit.bio's existing toolkit, underlining the company's leadership in cell programming technologies. As the world of biomedical research evolves, these innovative tools promise to significantly aid scientific exploration and unlock new pathways in understanding human health.

In conclusion, the launch of bit.bio's ioTracker Cells, particularly the GFP ioMicroglia, signals a pivotal advancement for researchers engaged in neuroscience. The ability to track and isolate cells effectively unveils opportunities for groundbreaking discoveries in drug development and the treatment of neural disorders.

For more information on purchasing bit.bio’s GFP ioMicroglia, visit their ioCells product catalog.